chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I received the first of 2 Vaccines in April 2021 and my hands have been numb since and my legs feel like I am walking on air; This spontaneous case was reported by a patient and describes the occurrence of HYPOAESTHESIA (I received the first of 2 Vaccines in April 2021 and my hands have been numb since and my legs feel like I am walking on air) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.    On 24-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced HYPOAESTHESIA (I received the first of 2 Vaccines in April 2021 and my hands have been numb since and my legs feel like I am walking on air). At the time of the report, HYPOAESTHESIA (I received the first of 2 Vaccines in April 2021 and my hands have been numb since and my legs feel like I am walking on air) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.  It was unknown if the patient experienced any additional symptoms/events. No treatment information was provided.
Pt had swollen tongue approx 6 hrs p/immun; pain & swelling @ inject site;
Got a bad sore throat  Got bad throat and Esophagus ? soreness ?and indigestion Shortness of breath  chest area soreness  I am not sure of the name but am sure that the lot# 131335P3D4H8RW and the other number I wrote down was- UJ899AB and exp- 30June23
shortness of breath/shallow breathing within 3 days after administration still ongoing after 3 weeks worsened at 3 weeks post injection to atelectasis
titers were inconclusive; This case was reported by a other health professional via call center representative and described the occurrence of therapeutic response decreased in a 19-year-old female patient who received Hepatitis B vaccine for prophylaxis.   Co-suspect products included Hepatitis B vaccine for prophylaxis and Hepatitis B vaccine for prophylaxis.   On an unknown date, the patient received the 1st dose of Hepatitis B vaccine, the 2nd dose of Hepatitis B vaccine and the 3rd dose of Hepatitis B vaccine. On an unknown date, unknown after receiving Hepatitis B vaccine, Hepatitis B vaccine and Hepatitis B vaccine, the patient experienced therapeutic response decreased. On an unknown date, the outcome of the therapeutic response decreased was unknown.  Additional details were provided as follows: The age at vaccination was not reported. The patient had completed a Hepatitis B vaccine series as a child had titers drawn and the titers were inconclusive, which led to therapeutic response decreased. The reporter consented to follow up. Brand name of previous HepB series was unknown.  Titers were drawn for this patient was starting nursing school.  The medical assistant stated additional patient details are not available at this time. The physician just asked the Medical Assistant to call and did not provide any further details.  The medical assistant consents to follow up from safety.
Both vaccinations were inadvertently given very high up, at the top of my arms. This was excruciatingly painful and resulted in immediate, severe nerve pain which radiated down both arms into my hands, as well as marked localized shoulder pain. The left side was worse than the right side. I was unable to open the car door in the parking lot of the clinic following the vaccinations (or perform any other manual tasks). The severe shoulder/arm/hand pain and dysfunction persisted to such an extent that I was unable to perform any manual tasks and required assistance for carrying out activities of daily living, etc. Severe loss of mobility of both shoulders occurred as well. I notified clinic on several occasions about the severity of my signs and sought treatment at 2 emergency clinics because I was out of state immediately following the vaccinations. Preliminary therapy with oral prednisone did not improve the situation, so Dr. performed an intrabursal corticosteroid injection on the left side (which was the most severely affected). Within 6-8 weeks post vaccination, profound muscle atrophy of the shoulders, arms, chest and upper back occurred. Physical therapy has been on-going. Because of the presence of an implanted medical device, it is not feasible to have an MRI. A bilateral shoulder arthrogram-CT scan was done instead. Currently, 10 months later, the localized shoulder pain persists, along with continued radiating arm/hand pain weakness and dysfunction. Results of EMG testing are pending.
had a break out of  Herpes Simplex; Headache; Muscle Ache; This case was reported by a physician via call center representative and described the occurrence of herpes simplex in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 13th July 2020, the patient received the 2nd dose of Shingrix. In July 2020, less than a week after receiving Shingrix, the patient experienced herpes simplex, headache and muscle pain. On an unknown date, the outcome of the herpes simplex, headache and muscle pain were unknown.   It was unknown if the reporter considered the herpes simplex, headache and muscle pain to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The patient received Shigrix and started to experience muscle ache, headache and had a break out of herpes simplex. The reporter did not consent to follow-up.
Information has been received from a registered nurse via a company representative referring to a 16 year old female patient. Information regarding concurrent conditions and medical history was not provided. On 14-AUG-2014 and 24-NOV-2014 the patient was vaccinated with the first and second dose of GARDASIL respectively, intramuscularly (dose, lot # and application site were not reported). Concomitant therapy was not reported. On 31-MAR-2015, the patient was in physician's office to receive dose three, but she mentioned that since she received the second dose on 24-NOV-2014, when she laid dose, her arm got numb in the area in which she received the GARDASIL injections. No treatment was given for event. None of lab diagnostics studies was performed. The physician recommended that the patient receive the third dose at this time. The nurse reported that she thought the "numbness" at the GARDASIL injection site that the patient had experienced an unspecified amount of times since an unspecified date (patient reported "Since injection of second dose") might be due to the patient being a "weight lifter". The outcome of event was reported as not recovered/not resolved. The causality was not reported. Additional information has been requested.
Sore arm at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Sore arm at the injection site) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006B21A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 (Covid-19; 6weeks before she passed.) in February 2022. Concurrent medical conditions included Latex allergy.    On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (Sore arm at the injection site). At the time of the report, VACCINATION SITE PAIN (Sore arm at the injection site) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported.  No treatment medication was reported.   This case was linked to MOD-2022-565183 (Patient Link).
The day after vaccine receipt, experienced flu-like symptoms and new onset diplopia, dysphasia, dysarthria, paresthesia, some difficulty with urination, ataxia and gait imbalance. Presented to ER about 3 days later, where he was found to be relatively hypertensive (He had stopped his antihypertensive medications 1 week prior). Symptoms stabilized at that point. On exam, pupils unreactive, eyes conjugate in primary gaze, severe ophthalmoplegia with bilateral abduction deficits. Left facial weakness more prominent in lower distribution. Absent vibration throughout with exception of sternum and skull. Profound decreased proprioception in the lower extremities. Reflexes 0-4 through all extremities, plantars flexor bilaterally. Moderately ataxic with finger to nose testing, heel to shin testing. Diagnosed with Miller Fisher Variant of GBS. Treated with IVIG with some improvement of speech and swallowing capabilities by 11/22. Pt transferred to rehab facility. (This is initial VAERS report. Will file follow up report additional history and medical records obtained).  4/6/07 Received medical records from WRAMC which reveal patient experienced flu like symptoms on 11/9/06 one day after vax of fever, chills, gen body aches, diplopia, difficulty w/speech & swallowing, dysuria, paresthesias of extremities, gait & balance problems, fall.  Symptoms continued x 2 days & then went to ER.  ER exam revealed HTN (had not taken med x approx 1 wk).  Admitted to hospital on 11/12/06. Neuro exam revealed pupils unreactive, severe ophthalmoplegia, left facial weanesss, absent vibration throughout except sternum & skull, profound proprioception in LEs.  Reflexes were absent in all 4 extremities.  Ataxia.  Required intubation for 5--6 days.  Tx w/IVIG.  By 11/22 exhibited slow improvement in speech & swallowing.  Transferred to inpatient Rehab facility on 11/24 & d/c to home from there on 12/1/06 w/continued outpatient therapy.  As of 3/07, still had paresthesias of extremities & is being followed by neuro.  LABS: EKG revealed LVH & NSR.  CXR was WNL.  CT of head revealed right mca hyperdensity at sylvian fissure c/w thrombus. CSF 196 & WBC 33, c/s neg..  Barium swallow was abnormal & revealed aspiration. FINAL DX: Miller-Fisher variant of GBS in temporal association w/vax. Per information from annual follow up: 2/14/08-Spoke to patient on phone. Still having double vision inperiperal fields and having numbness & tingling in hands and feet. No vaccines since intial presentation. See attached neuro notes from 4/07 and PCM visit in 7/07. Patient was placed on temporary disability. See enclosed disablity determination and Narrative summaries.
After a nap, woke to chills and flu like symptoms. Noticed ringing in my left ear. This has continued ever since and most locally in the left ear. It is now a year later and although I sometimes don't notice the ringing as much as I used to, it hasn't gone away. It is best for me not to focus on it or it'll drive me crazy.
My problem is a numbness and loss strength in same in the hand that I receive the left shoulder, in the left shoulder; My problem is a numbness and loss strength in same in the hand that I receive the left shoulder, in the left shoulder; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non-HCP). The reporter is the patient.  An 85-year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 18Oct2021 (Batch/Lot number: unknown) at the age of 85 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "I am hard to hearing" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE; no reaction or anything else), for Covid-19 immunization; Bnt162b2 (DOSE 2, SINGLE; no reaction or anything else), for Covid-19 immunization. The following information was reported: HYPOAESTHESIA (non-serious), MUSCULAR WEAKNESS (non-serious) all with onset Oct2021, outcome "unknown" and all described as "My problem is a numbness and loss strength in same in the hand that I receive the left shoulder, in the left shoulder". Therapeutic measures were not taken as a result of hypoaesthesia, muscular weakness.  Additional information: The patient received 3rd shot on 18Oct2021 (Confirmed as date of vaccination), say that again, she had no reaction or anything else on the first two shot. She stated that her problem was a numbness and loss strength in same in the hand that she received the left shoulder, in the left shoulder on the 18Oct2021 that was the 3rd shot and she have queries about others report on the same condition. Start date of adverse event was reported about 3 or 4 days ago. Patient's weight was 220 (unit not reported).  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
patient of age range of 59 to 62 received Fluzone High-Dose, no AE; patient of age range of 59 to 62 received Fluzone High-Dose, no AE; Initial information was received on 03-Mar-2020 regarding an unsolicited valid non-serious case from a consumer.  This case is linked to cases 2020SA059559 and 2020SA059552 (same reporter).  This case involves a patient (age range of 59 to 62) (gender unknown) who received a dose of INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [FLUZONE HIGH DOSE] (lot number and expiry date were not reported) via an unknown route at an unknown administration site for prophylactic vaccination in the last October to November.  Medical history, medical treatment, vaccination and family history were not provided.  It was a case of actual medication error due to inappropriate age at vaccine administration and overdose.   At the time of reporting, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holders compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.  Information on the batch number was requested.
pt recv vax;exp high fever but was "clinically well";devel a pustular rash on chest and back,consisting approx 30 lesions which was mildly pruritic;MD stated the rash did not look like typical chicken pox;rash lasted about 5 days;
Swelling and Redness at injected site/ left deltoid. Occurred at night on 12/7/27/21.
Hives, urticaria, MENVEO vaccine given 8-18-14 and pt developed hives 8-24-14; face looked swollen to mom on 8-23-14. Gave BENADRYL po at home in pm. ZYRTEC in am; saw Dr in office 8-25-14 Dx with virus vs reaction to MENACTRA.
Pt developed a fever approx 12hours after vaccine administration. He had mental status changes and fell in his home.
Myalgia, Arthralgia, WARMTH, TENDERNESS, AND ERYTHEMA TO LEFT DELTOID AT INJECTION SITE Narrative:
Upon immunization the pharmacy intern had to have hit a blood vessel as the patient began to bleed more than normal, her arm proceeded to instantly swell with obvious bleeding under the skin. Pharmacist intervened applied gentle pressure x 3 minutes upon which the swelling went down and bleeding stopped.
Soon after receiving the vaccine, once I was seated for the observation period, I noticed my eyesight was strained. It was hard to focus to see what was in front of me. At the time I was trying to watch a slideshow on the TV in the room with vaccine facts. This subsided, but came back the next day in the evening (around 5pm). I noticed this at 5pm while trying to work on my computer.
patient was inadvertently administered an expired Ipol vaccine/ No adverse event; Based on information previously received with Agency: 18-DEC-2018, the following information have been amended.   Initial information received on 18-Sep-2018 regarding an unsolicited valid non-serious case received from a nurse.  This case involves a 12 years old male patient (weight: 225.4, height: 67.5) who was inadvertently administered with a 0.5 ml (fourth dose) expired vaccine of IPV (VERO) [IPOL] (lot M1453 and Exp. Date not reported) via intramuscular route in the left deltoid.  The patient had a visit to the doctor on 18-Sep-2018.  The patients past medical history, medical treatment(s), vaccination(s) and family history were none.  Concomitant medication was not reported.  It was a case of actual medication error due to expired vaccine used.  No adverse event was experienced. reported as No signs or symptoms from expired vaccine.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive and Module VI of the Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.  Documents held by sender: none.  Follow up information was received from a nurse on 14-NOV-2018.  No new information added.  Follow up information was received from a nurse on 18-Dec-2018.  Information regarding medical history and family history updated.  Information regarding adverse event was updated. changes was made in the narrative accordingly.  List of documents held by sender: none.  Addendum: Based on information previously received with Agency: 18-DEC-2018, the following information have been amended.
Pt experienced a lightheaded feeling and dizziness after receiving his first dose of the Pfizer vaccine. Pt was then assisted in ambulating to the treatment area where he was placed in a supine position on a the medical cot. Pt never completely lost consciousness. Vitals were obtained every 5 minutes while in recovery. After approximately 2 minutes, the Pt began to feel better and was able to sit up with no negative symptoms. Pt remained in observation for another 15 minutes and was then released with no complications or incidents.
Dizziness; Fatigue; Headache; Chills; Nausea; A spontaneous report was received from a Consumer (reporting on self) concerning a 49-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events fatigue, headache, chills, nausea and dizziness.  The patient's medical history was not provided. Concomitant medications included Thyroid medications.  On 20 Jan 2021, approximately 4 days prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (lot/batch: 028L20A) intramuscularly in the left arm for prophylaxis of COVID-19 infection.  On 23 Jan 2021, the patient experienced the events fatigue, headache, chills, nausea and dizziness.  Treatment details included BC Powder.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of events of fatigue, headache, chills,  nausea, dizziness was not recovered.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Patient was administered the HPV, Bexero and Hepatits A vaccine. He became pale, diaphoretic and passed out. The episode lasted approximately 1 minute. Cold compresses and Sprite were supplied to the patient. Patient was moved to the floor. He completely recovered in approximately 15 minutes.
I got my Moderna vaccine in the left arm. It was on 4/20/22. Then around 5/3/22, we had a really bad storm, and we lost our power. I went downstairs to check on our freezer and going up the stairs I was getting whiffs of gas and it was very faint. After smelling it for a second time, a horrible headache began for several days. On a pain scale, it was around 7-8. I do have a history of migraines. It was really pounding, and it never stopped and went on for 4 days. Then it started to subside. I started getting pain in the back of neck on the left side. It felt like a muscle was pulled. My neck would get really stiff and I would get this tingling sensation after. These past few months since May, the tingling has traveled from my neck on the left side up to my ear then to my left temple. It would travel down the left side of face and I would start to get tingling in the left cheek. It will sometimes travel to my neck and front of throat. It feels like my throat is starting to close. I've seen my PCP about this and he didn't say much at first. I saw him again in August and he suggested to see a neurologist. Just got in last week to see a neurologist and she ordered an MRI. I also have a knee problem and I was on 15 mg of MOBIC and I've been on that for quite some time. I looked up more severe symptoms of MOBIC and things like blisters, double vision, tingling sensations, etc. came up. In September, I discontinued the medication on my own and some of the symptoms have subsided. They've lessened. I'm not sure what is going on. I'm not sure if the shot did some of this or the medication. I went and got my fifth booster yesterday and got Pfizer. I got that in my right arm. 45 minutes later when I was home, it was weird because I was getting the closing sensation on the left side of my neck and it felt like my throat was closing. It never closes to the point yet that I am short of breath or having difficulty breathing. I do have an EPIPEN for allergies. The last couple of months since April, I've had a lot of weird symptoms. I've had tremors in my hands. When I went off the MOBIC for about 5 weeks now, the tremors in my left hand are not as pronounced. There's nothing I can pinpoint that triggers any of this. The neurologist doesn't know what's going on. I can't get an MRI until the middle of January 2023, and I'm currently winging it. Any pains I take TYLENOL for. I'm not exactly sure if the shot precipitated any of this. It's just that all these things happened since the vaccine in April. Not sure if it was the shot or the medication, or what happened. During early May, I was also experiencing some short periods of dizziness and light headedness, but it wasn't hindering me of daily activities.
This case was reported by a pharmacist via call center representative and described the occurrence of facial swelling in a 56-year-old female patient who received SHINGRIX (batch number 5NY3B, expiry date 13th July 2020) for prophylaxis. Concurrent medical conditions included latex allergy. On 15th May 2018, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced facial swelling. SHINGRIX was discontinued. On an unknown date, the outcome of the facial swelling was recovered/resolved. It was unknown if the reporter considered the facial swelling to be related to SHINGRIX. Additional information was received as follows: The pharmacist reported an adverse event on behalf of the patient. At the time of reporting, the patient was approaching the date for the 2nd dose of SHINGRIX. The patient had dramatic swelling of face without rash or blotchiness. The swelling lasted for 3 to 4 days and then decreased to its normal state. The patient had decided not to get the 2nd dose of SHINGRIX. The reporter did not aware of any hospital visits in association to this event nor did he know how soon the swelling started after receiving the dose. The consent was provided for contacting the patient.
Vomiting and diarrhea from 4-7 am Tues morning. Followed by fatigue all day and Tues night.  Temp on Tues afternoon was 101.4. aches and chills periodically on Tues afternoon. Weakness on Tues morning into late afternoon. Temp 99.6 on wed morning and afternoon. Temp normal at 8pm wed.